Quotient Sciences Grows Its Drug Substance Manufacturing Facility

Quotient Sciences, a drug development and manufacturing accelerator, has completed the expansion of its drug substance manufacturing facility in Alnwick, UK. The $7 million project features a state-of-the-art drug substance manufacturing capability that can provide integrated support for customers, from candidate selection through to early clinical development and beyond.

The expansion delivers multipurpose capacity of up to 15 good manufacturing practice (GMP) reactor streams, with reactor volumes ranging from five liters up to 150 liters and tactical deployment of batch or continuous flow chemistry technologies to optimize drug substance manufacturing processes. The facility has been designed adopting Industry 4.0 principles, including a predictive process control system (PharmaMV) that works to improve the transfer from small-scale process research and development (PR&D) into manufacture of multi-kilogram quantities of drug substance for clinical use.

“Since acquiring the Alnwick facility in 2021, our objective has been to incorporate drug substance services into our integrated Translational Pharmaceutics platform combining drug product manufacturing and clinical testing,” explains Mark Egerton, PhD, Quotient Sciences CEO. “By working with customers at the point of candidate nomination, we can now design the most streamlined programs and significantly accelerate their development timelines.”